Close Menu

A high density of CD8 T cells, along with increased activity of a specific immune pathway, may help identify which metastatic prostate cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a report appearing in Science Translational Medicine. ICB has shown promise in treating advanced cancers but tends to be most effective against tumors with high mutational burden since there are neoantigens available for targeting by reinvigorated T cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.